Previous 10 | Next 10 |
2023-10-03 17:46:09 ET More than 80 stocks were identified by Morgan Stanley as potentially having technical pressure due to tax loss selling. A Morgan Stanley U.S. Equity Strategy report, published on Monday, showed 81 stocks that could have performance pressures due to market selling ...
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Comme...
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE...
2023-09-12 07:34:47 ET Repligen ( NASDAQ: RGEN ) has appointed Jason K. Garland as Chief Financial Officer, effective September 25, 2023. Jason succeeds retiring CFO Jon K. Snodgres, who will continue in a full-time advisory role until his October 6, working closely with&...
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer (“CFO”), effective September 25, 2023. Mr....
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 6 -8 in Boston. Tony J. Hunt, Pre...
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment installation, footprint, and maintenance requirements WALTHAM, Mass., Aug. 17, 2023 (...
2023-08-02 15:26:10 ET Repligen Corporation (RGEN) Q2 2023 Earnings Conference Call Aug 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Offi...
2023-08-02 07:34:29 ET Repligen press release ( NASDAQ: RGEN ): Q2 GAAP EPS of $0.53 beats by $0.21 . Revenue of $159.2M (-23.3% Y/Y) misses by $6.72M . Adjusts full year revenue guidance to range of $635-$665 million. Gross margin is expected to be 49.5%-5...
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corpo...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...